Blood cancers

BTK inhibitors go head-to-head in Waldenström macroglobulinemia

The more selective BTK inhibitor zanubrutinib offers better tolerability and possibly better efficacy than ibrutinib for patients with Waldenström macroglobulinemia, an Australian study has shown. Presented at the ASCO 2020 virtual meeting by Professor Con Tam of the Peter MacCallum Cancer Centre in Melbourne, the results of the ASPEN Phase III study showed zanubrutinib was ...

Already a member?

Login to keep reading.

© 2021 the limbic